GeneDx Holdings Corp.
WGS
$56.33
$4.538.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.16% | 37.81% | 49.44% | 50.26% | 52.07% |
| Total Other Revenue | 222.64% | 238.54% | 119.32% | -13.79% | -52.01% |
| Total Revenue | 34.09% | 39.97% | 50.50% | 48.70% | 48.81% |
| Cost of Revenue | 17.52% | 16.54% | 12.80% | 9.90% | 3.71% |
| Gross Profit | 42.90% | 53.34% | 76.17% | 79.69% | 93.63% |
| SG&A Expenses | 43.28% | 38.36% | 27.89% | 14.09% | 5.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.27% | 33.66% | 23.67% | 11.37% | 1.34% |
| Operating Income | -136.24% | 49.60% | 119.95% | 107.08% | 88.04% |
| Income Before Tax | -101.81% | 59.84% | 102.98% | 101.30% | 71.75% |
| Income Tax Expenses | 79.57% | 66.18% | 158.08% | 115.20% | 121.60% |
| Earnings from Continuing Operations | -101.70% | 59.80% | 102.49% | 101.20% | 71.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.70% | 59.80% | 102.49% | 101.20% | 71.43% |
| EBIT | -136.24% | 49.60% | 119.95% | 107.08% | 88.04% |
| EBITDA | -206.30% | 700.76% | 239.39% | 158.40% | 108.83% |
| EPS Basic | -84.38% | 63.35% | 102.42% | 100.78% | 72.58% |
| Normalized Basic EPS | -18.70% | 65.30% | 123.46% | 113.88% | 79.37% |
| EPS Diluted | -85.13% | 62.51% | 101.84% | 100.37% | 72.51% |
| Normalized Diluted EPS | -20.33% | 64.26% | 122.90% | 113.46% | 79.37% |
| Average Basic Shares Outstanding | 5.58% | 6.52% | 7.21% | 6.92% | 6.26% |
| Average Diluted Shares Outstanding | 6.65% | 7.61% | 8.32% | 8.04% | 6.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |